Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2052

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2052
---
You
should read this summary together with the description of each risk factor contained in Item 1A of this Report, as well as other documents
to be filed by us from time to time with the SEC, for a more detailed discussion of certain risks that could materially adversely affect
our financial conditions and the market price of our securities. The following list describes some of our principal risk factors after
the Closing of the Business Combination:

    ●
    We
    have incurred significant net losses since inception and we are expected to continue to incur significant net losses for the foreseeable
    future.

    ●
    We
    may not be successful in our efforts to use our differentiated business model to build a pipeline of product candidates with commercial
    value.

    ●
    We
    will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on
    acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future
    commercialization efforts and/or other operations.

    ●
    We
    are a biopharmaceutical company with a limited operating history, and many of our development programs are in early stages of development.
    This may make it difficult to evaluate our prospects and likelihood of success.

    ●
    Our
    underlying technology is unproven and may not result in marketable products.

    ●
    Because
    we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development
    materials may become limited or interrupted or may not be of satisfactory quantity or quality.

    ●
    Even
    if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians,
    patients, third-party payors and others in the medical community necessary for commercial success.

    ●
    The
    market opportunities for our product candidates may be relatively small since the patients who may potentially be treated with our
    product candidates are those who are ineligible for or have failed prior treatments, and our estimates of the prevalence of our target
    patient populations may be inaccurate.

    ●
    We
    rely on third parties to conduct all or certain aspects of our preclinical studies and clinical trials. If these third parties do
    not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be
    able to obtain regulatory approval of or commercialize any potential